OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong

- April 12th, 2016

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced that the Company has received a Notice of Allowance for a patent on ProscaVax®, OncBioMune’s cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from Hong Kong’s patent office.

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced that the Company has received a Notice of Allowance for a patent on ProscaVax®, OncBioMune’s cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from Hong Kong’s patent office.
As quoted in the press release:

ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigen PSA with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune is in the process of enrolling and treating the final four patients in a Department of Defense-funded Phase 1a trial of ProscaVax in late-stage cancer patients hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California. As recently disclosed, OncBioMune is using the data from the Phase 1a trial, that shows very minimal toxicity of ProscaVax, to forego the Phase 1b portion of the ongoing trial and to initiate two Phase 2 clinical trials of ProscaVax in 2016. One study is planned to be hosted at a major university in the Northeast United States and will enroll early-stage cancer patients in the “active surveillance” population. The second, to be conducted in Mexico through a joint venture with Vitel Laboratorios S.A. de C.V., will evaluate ProscaVax for the treatment of PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients.
Prostate cancer is the third most common cancer in men in Hong Kong, accounting for approximately 11.1 percent of all newly diagnosed cancer cases annually.

OncBioMune Pharmaceuticals CEO, Dr. Jonathan Head, stated:

As we’ve shown with our recent partnership to develop and commercialize ProscaVax throughout Mexico and Latin America, we intend to remain active in exploring opportunities worldwide for our novel vaccine. Prostate cancer is a global problem with limited treatments that are safe and effective without morbidities. Given that ProscaVax has the potential to treat the disease at any stage, patents to protect our intellectual property are very important for our ongoing developmental efforts.

Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.

Leave a Reply